Clinical Research on DONA®

Dona® contains the original Crystalline Glucosamine Sulfate, a specific type of glucosamine sulfate developed and sold in more than 60 countries around the world. Invented and patented by RottaPharm, Crystalline Glucosamine Sulfate offers a method to stabilize glucosamine sulfate, through a chemical process of co-precipitation with sodium chloride, thus obtaining Crystalline Glucosamine Sulfate.

Dona® is supported by product specific clinical data and has been evaluated in over 7,000 patients in over 25 clinical trials. Through its unique formulation, Dona® offers a stable form of glucosamine which is able to reach joints in the right place and with the right concentration.

Below are highlights from some scientific publications that specifically used Dona®

• Results of the first 3-year study were published in 2001 in The Lancet, a prestigious, international medical journal, and showed Crystalline Glucosamine Sulfate to be effective in improving and maintaining joint flexibility and cartilage health.

• In 2002, a second 3-year study was published in the JAMA's Archives of Internal Medicine confirming previous findings and suggesting that Crystalline Glucosamine Sulfate could be used to help maintain and stabilize joint function and cartilage.

• An 8-year observational study was later conducted on patients taking glucosamine sulfate for 3 years and 5 years off. It found that Glucosamine Sulfate not only was beneficial for joint health but it decreases the chance of total knee replacement by 73%.

• In a 6-month controlled clinical trial called the GUIDE Trail, it showed that Glucosamine Sulfate's efficacy on knee symptoms was significantly better on all parameters as compared to placebo and acetaminophen.